COMPARATIVE STUDY ON THE BENEFICIAL EFFECTS OF TELMISARTAN AND OTHER ANTIHYPERTENSIVE AGENTS IN STROKE PATIENTS
DOI:
https://doi.org/10.22159/ijpps.2017v9i2.15755Keywords:
NIHSS, Anti-hypertensive agents, Telmisartan, StrokeAbstract
Objective: To compare the beneficial effects of telmisartan with other anti-hypertensive agents during stroke with respect to improvement from neurological dysfunction.
Methods: A prospective observational study was performed on 98 eligible study participants. The blood pressure, National Institute of Health Stroke Scale (NIHSS) score and power of limbs were noted. The data were analysed using one-way Analysis Of Variance (ANOVA) followed by Dunnett's Multiple Comparison Test.
Results: Among 150 randomised patients, 110 met the inclusion criteria, and 98 came for follow-up whose data was recorded. Telmisartan showed significant improvement in total NIHSS score compared to amlodipine (P ≤ 0.01) and mannitol (P ≤ 0.01). The mean reduction in SBP and DBP was significant with respect to telmisartan compared to amlodipine (P≤ 0.01). Telmisartan showed significant improvement of power in right upper limb (UL) compared to amlodipine (P ≤ 0.05) and mannitol (P ≤ 0.01). Improvement of power in right lower limb (LL) showed significance with respect to telmisartan compared to mannitol (P ≤ 0.05). Significant improvement of power in left LL was observed in telmisartan compared to mannitol (P ≤ 0.01).
Conclusion: Blood pressure reduction is an inevitable component of stroke treatment. Anti-hypertensive treatment seems to be highly efficacious in protecting patients against stroke and stroke recurrence, especially on long term basis. Thus, telmisartan provides a viable insight into the stroke prevention strategy and may be prudent to consider as a reasonable add-on therapy.
Downloads
References
Thone-Reineke, Steckelings Um, Unger T. Angiotensin receptor blockers and cerebral protection in stroke. J Hypertens 2006;24 Suppl 1:115-21.
Kakuta H, Suboh K, Sasamata M, Yamaqishi S. Telmisartan has the strongest binding affinity to angiotensin–II type 1 receptor: comparison with another angiotensin–II type 2 receptor blockers. Int J Clin Pharmacol Res 2005;25:41-6.
Vasilios Papademetriou, C Farsang, D Elmfeldt. Stroke prevention with the angiotensin-II type 1 receptor blocker, Candesartan in elderly patients with isolated systolic hypertension: a study on cognition and prognosis in the elderly (SCOPE). J Am Coll Cardiol 2004;44:1175-80.
Paulette A Lyle, Kjeldsen SE, Kizer JR. The effect of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy: the LIFE study. J CLIN Hypertens 2005;7:152-8.
Venkatesh Aiyagari, Philip B Gorelick. Management of blood pressure for acute and recurrent stroke. STROKE AHA 2009;40:2251-6.
Mann JF, Anderson C, Gao P. Dual inhibition of rennin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: the result of ONTARGET trial. J Hypertens 2013;31:414-21.
D Giri Rajasekhar, D Guru Prasanna, P Chandrakanth. Prescribing pattern of antihypertensive drugs based on compelling indications with hypertension. IAS 2016;8:72-5.
Devender Kodati, Harikiran Lingabathula, Narsimha Reddy Yellu. Effect of Olmesartan and Labetolol on oxidative stress and antioxidant status in south Indian hypertensive patients. Asian J Pharm Clin Res 2016;9:307-10.
Bjorn Dahlof. Prevention of stroke: new evidence. Eur Heart J 2009;11 Suppl 1:33-8.
Fuentes B, Fernandez-Dominquez J, Ortega-Casarrubios MA, San Jose B, Martinez-Sanchez P, Diez-Tejedor E. Treatment with angiotensin receptor blockers before stroke could exert a favorable effect in acute cerebral infarct. J Hypertens 2010;28:575-81.
Gui Jv Chen, Mao Sheng Yang. The effects of CCB’s in the prevention of stroke in adults with hypertension: a meta-analysis of data from 273,543 participants in 31 randomised controlled trials. PLOS One 2013;8:1-9.
Jose Castillo, Rogelio Leira, Maria M Garcia, Joaquin Serena, Miguel Blanco, Antoni Davalos. Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. Stroke 2004;35:520-6.
Meng Lee, Jeffrey L Saver, Keun-Sik Hong, Quing Hao, Jessica Chow, Bruce Ovbiagele. Renin-angiotensin system modulators modestly reduce vascular risks in persons with prior stroke. Stroke 2012;43:113-9.
Liu Lisheng, Wang, Ji-Guang, Gong L, Liu G, Staesscn JA. Comparison of the active treatment and placebo in older Chinese patients with isolated systolic hypertension in China (Syst-China) collaborative group. J Hypertens 1998;16:1823-9.
Volpe M, Ruilope LM, Mclnnes GT, Waeder B, Weber MA. Angiotensin–II receptor blockers: benefits beyond blood pressure reduction? J Hum Hyperten 2005;19:331-9.
Paolo Verdecchia, Gentile G, Angeli F, Reboldi G. Beyond blood pressure: Evidence for cardiovascular, cerebrovascular and renal protective effects of Rennin-angiotensin system blockers. Ther Adv Cardiovasc Dis 2012;6:81-91.
Parveen Rashid, Jo Leonardi-Bee, Phillp Bath. Blood pressure reduction and secondary prevention of stroke and other vascular events. Stroke 2003;34:2741-8.
Bath PM, Martin RH, Paleschy. Effect of telmisartan on functional outcome, recurrence and blood pressure in patients with acute mild ischemic stroke. A PRoFESS subgroup analysis. Stroke 2009;40:3541-6.
Roberta Ravenni, Joe F Jabere, Edoardo Casiglia, Alberto Mazza. Primary stroke prevention and hypertension treatment: which is first line therapy? Neurol Int 2011;3:12.
SG Chrysant. Angiotensin receptor blocker provides better stroke protection than angiotensin converting enzyme inhibitors–a hypothesis with clinical and experimental support. Hippokratia 2005;9:99-105.
Unger. Blood pressure is lowering and rennin-angiotensin system blockade. J Hypertens 2003;21 Suppl 1:3-7.
Weber. The telmisartan programme of research to show telmisartan end-organ protection programme. J Hypertens 2003;6 Suppl 1:37-46.
Published
How to Cite
Issue
Section
